Journal article
Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review
B Merkel, H Butzkueven, AL Traboulsee, E Havrdova, T Kalincik
Autoimmunity Reviews | Published : 2017
Abstract
Background Immunotherapy initiated early after first presentation of relapsing-remitting multiple sclerosis is associated with improved long-term outcomes. One can therefore speculate that early initiation of highly effective immunotherapies, with an average efficacy that is superior to the typical first-line therapies, could further improve relapse and disability outcomes. However, the most common treatment strategy is to commence first-line therapies, followed by treatment escalation in patients who continue to experience on-treatment disease activity. While this monitoring approach is logical, the current lack of effective regenerative or remyelinating therapies behoves us to consider hig..
View full abstractRelated Projects (5)
Grants
Awarded by Multiple Sclerosis Society
Funding Acknowledgements
This work was comissioned by the Multiple Sclerosis Society (UK) [programme award nr. 46]. The authors have received funding from National Health and Medical Research Council [project grants 1083539, 1032484 and 1129189, practitioner fellowship 1080518, and centre for research excellence 1001216], University of Melbourne [Faculty of Medicine, Dentistry and Health Sciences research fellowship] and the Czech Ministry of Education [project grant PRVOUK-P26/LF1/4].